7. Literature

1. Manger WM, Gifford RW. 100 Questions and answers about hypertension. In: 100 Questions and answers. 1 ed: Blackwell Science; 2000:1-9.

2. Manger WM, Gifford RW. 100 Questions and answers about hypertension. In: 100 Questions and answers. 1 ed: Blackwell Science; 2000:48.

3. Hricik D. Questions and answers about the diagnosis and management of hypertension. In: Hypertension secrets. 1 ed: Lippincott Williams & Wilkins; 2002:31.

4. Resende MM, Mill JG. Alternate Angiotensin II-forming pathways and their Importance in -Physiological or Physiopathological Conditions. Arq Bras Cardiol 2002;78(4):432-8.

5. Thomas WG, Mendelsohn FA. Angiotensin receptors: form and function and distribution. Int J Biochem Cell Biol 2003;35(6):774-9.

6. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52(3):415-72.

7. Li Q, Zhang L, Pfaffendorf M, van Zwieten PA. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br J Pharmacol 1995;116(7):2963-70.

8. Reaux A, Fournie-Zaluski MC, David C, et al. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A 1999;96(23):13415-20.

9. Albiston AL, McDowall SG, Matsacos D, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001;276(52):48623-6.

10. Ganten D, Schelling P, Vecsei P, Ganten U. Iso-renin of extrarenal origin. "The tissue angiotensinogenase systems". Am J Med 1976;60(6):760-72.

11. Lilly LS, Pratt RE, Alexander RW, et al. Renin expression by vascular endothelial cells in culture. Circ Res 1985;57(2):312-8.

12. Rosenthal JH, Pfeifle B, Michailov ML, Pschorr J, Jacob IC, Dahlheim H. Investigations of components of the renin-angiotensin system in rat vascular tissue. Hypertension 1984;6(3):383-90.

13. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res 1979;44(4):540-4.

14. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984;2(3):277-84.

15. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66(4):883-90.

16. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens Suppl 1994;12(9):S17-22.

17. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32(3):387-92.

18. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J 1995;16 Suppl N:79-85.

19. Belgardt S. Dissertation aus dem Fachbereich Medizin der Freien Universität Berlin. 2004.

20. Skeggs LT, Jr., Marsh WH, Kahn JR, Shumway NP. The purification of hypertension I. J Exp Med 1954;100(4):363-70.

21. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87(5):E1-9.

22. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase. J Biol Chem 2002;277(17):14838-43.

23. Changaris DG, Miller JJ, Levy RS. Angiotensin II generated by a human renal carboxypeptidase. Biochem Biophys Res Commun 1986;138(2):573-9.

24. Azaryan A, Barkhudaryan N, Galoyan A. Some properties of human and bovine brain cathepsin B. Neurochem Res 1985;10(11):1511-24.

25. Dorer FE, Lentz KE, Kahn JR, Levine M, Skeggs LT. A comparison of the substrate specificities of cathepsin D and pseudorenin. J Biol Chem 1978;253(9):3140-2.

26. Wintroub BU, Klickstein LB, Watt KW. A human neutrophil-dependent pathway for generation of angiotensin II. Purification of the product and identification as angiotensin II. J Clin Invest 1981;68(2):484-90.

27. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 1982;257(24):15042-6.

28. Haas E, Lewis LV, Scipione P, Koshy TJ, Varde AU, Renerts L. Angiotensin-producing enzyme I of serum: formation by immunization with renin. J Hypertens 1984;2(2):131-40.

29. Haas E, Lewis LV, Scipione P, Koshy TJ, Varde AU, Renerts L. Angiotensin-producing serum enzyme II. Formation by inhibitor removal and proenzyme activation. Hypertension 1985;7(6 Pt 1):938-47.

30. Haas E, Lewis L, Koshy TJ, Varde AU, Renerts L, Bagai RC. Angiotensin II-producing enzyme III from acidified serum of nephrectomized dogs. Am J Hypertens 1989;2(9):696-707.

31. Ideishi M, Sasaguri M, Ikeda M, et al. Angiotensin-converting activity of tissue kallikrein. Nephron 1990;55 Suppl 1(9):62-4.

32. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system'. Nature 1980;288(5792):705-6.

33. Berg T, Schoyen H, Wassdal I, Hull R, Gerskowitch VP, Toft K. Characterization of a new kallikrein-like enzyme (KLP-S3) of the rat submandibular gland. Biochem J 1992;281 (Pt 3):819-28.

34. Page I, Helmer O. Crystalline pressure substance (angiotonin) resulting from the action between renin and renin activator. J Exp Med 1940;71:29-50.

35. Munoz JM, Braun-Menendez E. Hypertensin: the substance causing renal hypertension. Nature 1939;144:980-81.

36. Cemassieux S, Boucher R, Crise C, Genest J. Purification and characterization of tonin. Can J Biochem 1976;54(9):788-95.

37. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substances and a proposed kinin-tensin system. Nature 1980;288:705-6.

38. Arakawa K. Serine protease angiotensin II systems. J Hypertens Suppl 1996;14(5):S3-7.

39. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417(6891):822-8.

40. Skidgel RA, Alhenc-Gelas F, Campbell WB. Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Prologue: Kinins and related systems. New life for old discoveries. Am J Physiol Heart Circ Physiol 2003;284(6):H1886-91.

41. Schluter H, Jankowski J, Rykl J, et al. Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system. Anal Bioanal Chem 2003;377(7 - 8):1102-7.

42. Schluter H, Jankowski J. Displacement Chromatography. In: Kastner M, ed. Protein Liquid Chromatography. Amsterdam: Elsevier; 2000.

43. Thiemann J, Jankowski J, Rykl J, et al. Principle and applications of the protein-purification-parameter screening system. J Chromatogr A 2004;1043(1):73-80.

44. Hofstee BH. Hydrophobic affinity chromatography of proteins. Anal Biochem 1973;52(2):430-48.

45. Garfin DE. One-dimensional gel electophoresis. Methods Enzymol 1990;182:425-41.

46. Nielsen TB, Reynolds JA. Measurements of molecular weights by gel electrophoresis. Methods Enzymol 1978;48:3-10.

47. Neville DMJ. Molecular Weight Determination of Protein-Dodecyl Sulfate Complexes by Gel Electrophoresis in a Discontinuous Buffer System. J Biol Chem 1971;246(20):6328-34.

48. Garfin DE. Isoelectric focussing. Methods Enzymol 1990;182:459-79.

49. Rabilloud T. Identification of proteins using peptide mass fingerprint. In: Proteome Research: Springer; 2000:218.

50. 2D Electrophoresis Large Scale Format User's Manual. WITA GmbH Teltow. (Accessed at www.wita.de.)

51. Klose J, Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implication for a functional analysis of the genome. Electrophoresis 1995;16(6):1034-59.

52. Gobom J, Mueller M, Egelhofer V, Theiss D, Lehrach H, Nordhoff E. A calibration method that simplifies and improves accurate determination of peptide molecular masses by MALDI-TOF MS. Anal Chem 2002;74(15):3915-23.

53. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971;20(7):1637-48.

54. Russo FS, Persson AV, Wilson IB. A fluorogenic substrate for angiotensin-converting enzyme in plasma. Clin Chem 1978;24(9):1539-42.

55. Huggins CG, Thampi NS. A simple method for the determination of angiotensin I converting enzyme. Life Sci 1968;7(12):633-9.

56. Tonnaer JA, Verhoef J, Wiegant VM, de Jong W. Separation and quantification of angiotensins and some related peptides by high-performance liquid chromatography. J Chromatogr 1980;183(3):303-9.

57. Wallenfels K. ß-Galactosidase (Crystalline). Methods Enzymol 1962;5:212.

58. Reinders J, Lewandrowski U, Moebius J, Wagner Y, Sickmann A. Challenges in mass spectrometry-based proteomics. PROTEOMICS 2004;4(12):3686-703.

59. Kang MJ, Tholey A, Heinzle E. Application of automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the measurement of enzyme activities. Rapid Commun Mass Spectrom 2001;15(15):1327-33.

60. Rossomando EF. Ion-exchange chromatography. Methods Enzymol 1990;182:309-17.

61. Sasaguri M, Maeda H, Noda K, et al. Purification and characterization of a kinin- and angiotensin II-forming enzyme in the dog heart. J Hypertens 1997;15(6):675-82.

62. Sasaguri M, Noda K, Tsuji E, et al. Structure of a kallikrein-like enzyme and its tissue localization in the dog. Immunopharmacology 1999;44(1-2):15-9.

63. Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 1993;3(6):327-32.

64. Salvesen G. Cathepsin G. In: Handbook of proteolytic enzymes. 1 ed: Academic press; 1998:60-2.

65. Ramaha A, Patston PA. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. Arch Biochem Biophys 2002;397(1):77-83.

66. Powers JC, Tanaka T, Harper JW, et al. Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors. Biochemistry 1985;24(8):2048-58.

67. Cavarra E, Martorana PA, Cortese S, Gambelli F, Di Simplicio P, Lungarella G. Neutrophils in beige mice secrete normal amounts of cathepsin G and a 46 kDa latent form of elastase that can be activated extracellularly by proteolytic activity. Biol Chem 1997;378(5):417-23.

68. Salvesen G, Farley D, Shuman J, Przybyla A, Reilly C, Travis J. Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic T lymphocyte proteinases. Biochemistry 1987;26(8):2289-93.

69. Legedz L, Randon J, Sessa C, et al. Cathepsin G is associated with atheroma formation in human carotid artery. J Hypertens 2004;22(1):157-66.

70. Kargi HA, Campbell EJ, Kuhn C. Elastase and cathepsin G of human monocytes: heterogeneity and subcellular localization to peroxidase-positive granules. J Histochem Cytochem 1990;38(8):1179-86.

71. Travis J. Structure, function, and control of neutrophil proteinases. Am J Med 1988;84(6A):37-42.

72. Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases:potetentional key regulators of cell signalling during inflammation. J Intern Med 2005;257:319-28.

73. ID_No_ 205653_at in Human GeneAtlas GNF1H, gcRMA. (Accessed at http://symatlas.gnf.org/SymAtlas/.)

74. Uhlen M, Ponten F. Antibody-based Proteomics for Human Tissue Profiling. Mol Cell Proteomics 2005;4(4):384-93.

75. , 2005. (Accessed at http://proteinatlas.org/tissue_profile.php?antibody_id=110.)

76. , 2006. (Accessed at http://www.labvision.com/pdf/1835.pdf.)

77. Wright CD, Kennedy JA, Zitnik RJ, Kashem MA. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor. Biochem Biophys Res Commun 1999;254(3):614-7.

78. Ohlsson S, Ljungkrantz I, Ohlsson K, Segelmark M, Wieslander J. Novel distribution of the secretory leucocyte proteinase inhibitor in kidney. Mediators Inflamm 2001;10(6):347-50.

79. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995;25(2):155-61.

80. Mervaala E, Muller DN, Schmidt F, et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35(2):587-94.

81. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001;79(2-3):76-102.

82. Gibbons GH, Dzau VJ. The Emerging Concept of Vascular Remodeling. N Engl J Med 1994;330(20):1431-8.

83. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005;11(6):RA194-205.

84. Stewart TA, Weare JA, Erdos EG. Human peptidyl dipeptidase (converting enzyme, kininase II). Methods Enzymol 1981;80 Pt C:450-60.

85. Ghosh SS, Said-Nejad O, Roestamadji J, Mobashery S. The first mechanism-based inactivators for angiotensin-converting enzyme. J Med Chem 1992;35(22):4175-9.

86. Oshima G, Gecse A, Erdos EG. Angiotensin I-converting enzyme of the kidney cortex. Biochim Biophys Acta 1974;350(1):26-37.

87. Caughey GH. Chymase. In: Handbook of proteolytic enzymes. 1 ed: Academic press; 1998:66-70.

88. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005;99(1):6-38.

89. Reilly CF, Schechter NB, Travis J. Inactivation of bradykinin and kallidin by cathepsin G and mast cell chymase. Biochem Biophys Res Commun 1985;127(2):443-9.

90. Ikeda M, Arakawa K. Kininogenase activity of tonin. Hypertension 1984;6(2 Pt 1):222-8.

91. Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol 2000;278(4):H1069-74.

92. Blais C, Drapeau G, Raymond P, et al. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am J Physiol Heart Circ Physiol 1997;273(5):H2263-71.